Macrophage-Involved Immuno-Oncology Models for In Vivo Testing

Macrophage-involved Immuno-oncology Models Serve as Important Tools for In Vivo Testing

Various immunotherapies and anticancer drugs have achieved certain success in cancer treatment, and preclinical evaluation of these drugs and therapies is an essential step before applied to clinical. However, there are a limited number of models available to evaluate the interaction between the human immune system and tumors. Evidence shows that macrophages are powerful immune effector cells that play important functions in tumor immunotherapy. Given the active role of macrophages in therapeutic strategies, they have become potential targets for improved cancer treatment. Therefore, it is crucial to develop macrophage-involved immuno-oncology models for in vivo testing.

Macrophages play an important role in cancer. Fig. 1 Macrophages play an important role in cancer.1

Our Macrophage-Involved Immuno-Oncology Models for In Vivo Testing

To evaluate the effectiveness against tumors in animal models, Creative Biolabs succeeded in developing macrophage-involved immuno-oncology models for in vivo testing. We employ the co-inoculation approach to generate macrophage-involved immuno-oncology models co-inoculated with CD3+ T cells, induced macrophage, and cancer cells. Based on this, we provide multiple types of macrophage-involved immune-oncology models for global customers’ immediate use. In addition, we are confident in providing customized solutions to develop a model that is appropriate for your diverse demands. Noteworthy, we also offer other types of immune-oncology models (i.e., DCs-involved immune-oncology models) to support your projects. Together with our top-ranking research team, we have more confidence in helping every customer to:

Here we provide a wide range of selected humanized immunodeficient mouse models used in immuno-oncology:

Strains Mouse models
General strains B-NDG; BRG; C57BL/6-RG; CIEA BRG; CIEA NOG; NCG; NOG; NRG; NOD-RG; NSG; NSI
MHC-affected strains with genetic alterations DRAGA; HUMAMICE; NOG-dKO or NOG-B2Mnull, IAnull; NOG I-Abeta <-/->; NSG-A2/DR1; NSG-B2Mnull IA IEnull; NSG-(KbDb)nullIAnull
Genetically modified strains for cytokine overexpression BRGST; hIL2-NOG; MISTRG; MISTRG6; NOG-EXL; NSG-SGM3
Other genetically modified strains BRGS; BRGSKW-v; NBSGW; NOG-pRorc γc; NSG-W41; TKO

Advantages of Our Macrophage-Involved Immuno-Oncology Models

As a leading company in the tumor research industry, Creative Biolabs is constantly developing more effective tools to evaluate anti-cancer drugs and immunotherapies in preclinical examination. If you want to know more details about our macrophage-involved immune-oncology models for in vivo testing, please get in touch with us without hesitation. We will try our best to deliver the best service for you.

Reference

  1. Duan, Zhaojun, and Yunping Luo. "Targeting macrophages in cancer immunotherapy." Signal transduction and targeted therapy 6.1 (2021): 127.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2025 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.